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Summary The effect of the month of diagnosis on survival was investigated in two series of unilateral
invasive breast cancer, of which one comprised 95% of all such histologically diagnosed breast carcinomas in
the city ofTurku, Finland, in 1945 to 1965 (n = 401), and the other 94% of all such carcinomas diagnosed in
1980 to 1984 (n = 337). If the histological diagnosis was made in January, February, or August to October in
1945-65, or in July to September in 1980-84, mortality in breast cancer was greater than if the diagnosis was
made during the rest of the year (P = 0.03 and 0.009, respectively). Cancers diagnosed during the
unfavourable months had more tumour necrosis in both series, and higher mitotic count and larger tumour
size in the 1945-65 series. The number ofdiagnosed cases was usually less than the median during the months
associated with unfavourable prognosis. Hypotheses to explain the altering prognosis by the month of
diagnosis include seasonal hormonal changes and social factors.
The season of initial discovery of tumour has recently been
described to be an independent variable predicting survival in
breast cancer (Mason et al., 1990), and women who detect
their breast cancer in spring or summer were found to have
more favourable survival as compared with those detecting
their tumour at other seasons of the year. It has been sug-
gested that the season of first detection of breast cancer may
reflect seasonal changes in hormone dependent growth
(Mason et al., 1990).
In the present study we evaluated the effect of the month
of diagnosis on prognosis of breast cancer in two series with
different length of follow-up from the same city. The results
show that breast cancers diagnosed in different months of the
year carry somewhat different prognosis, and the possible
explanations for this are explored.
Materials and methods
Patients
During the time period from 1945 to 1965, 461 cases of
female breast cancer were histologically diagnosed in the city
of Turku in South-Western Finland. The patients were col-
lected from the files of the Department ofPathology, Univer-
sity of Turku, the Turku University Central Hospital, the
City Hospital of Turku, and the Finnish Cancer Registry,
which was founded in 1952. Twenty-two patients were
treated elsewhere, were lost to follow-up, or had insufficient
clinicopathologic data, and women with either intraductal
(n = 15) or bilateral breast cancer (n = 23) were excluded,
leaving 401 patients in the final analysis (95% of all women
with histologically diagnosed, unilateral, and invasive breast
cancer in the city of Turku in 1945 to 1965). The median
follow-up time was 27 years (range, from 22 to 42 years).
According to data from the Finnish Cancer Registry 404
cases of female breast cancer were diagnosed in Turku in
1980 to 1984. After histological review, nine cases were either
benign tumours or some other type of cancer than breast
carcinoma. In two cases no biopsy had been taken and in
one case it was taken at autopsy, and in 22 cases either an
adequate histological sample or clinical data was lacking.
Women with either intraductal (n = 11) or bilateral cancer
(n = 22) were excluded, leaving 337 patients in the final
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analysis (94% of all women with histologically diagnosed,
unilateral, and invasive breast cancer in the city of Turku in
1980 to 1984). The median follow-up time was 6 years
(range, from 4 to 9 years). The hospital records and autopsy
protocols were reviewed, and follow-up information was
available for all 738 patients in the study.
of the diagnosis were considered to be postmenopausal.
Estrogen (ER) receptor analysis performed with the dextran
coated charcoal method was available in 263 cases (78%),
and progesterone receptor (PR) content in 238 (71%) cases
of the 1980-84 series. Radical mastectomy was performed in
228 (57%) and 168 (50%) patients, mastectomy and axillary
evacuation in 88 (22%) and 132 (39%), mastectomy in 60
(15%) and 32 (10%), partial mastectomy in 20 (5%) and two
(1%), and biopsy only in 5 (1%) and two (1%) patients in
1945-65 and in 1980-84, respectively. Postoperative
orthovoltage radiotherapy was given to 278 (69%) patients in
1945-65, and megavoltage therapy to 182 (54%) in 1980-84.
Adjuvant therapy with cyclophosphamide, methotrexate and
5-fluorouracil (CMF) was given to nine (3%) patients and
adjuvant tamoxifen to 28 (8%) in 1980-84.
Histology andflow cytometry
New hematoxylin-eosin and van Gieson stained slides were
prepared from each tissue block, and the original slides were
reviewed. The histological typing and grading was done
slightly modifying the WHO classification (1981) by one
pathologist (S.T.), and the tumours were classified into three
types: (1) infiltrating ductal carcinoma NOS (not otherwise
specified, includes apocrine, mixed mucinous, and atypical
medullary types), (2) infiltrating lobular carcinoma with
variants, and (3) other special types (includes tubular, medul-
lary, cribriform, papillary, metaplastic and pure mucinous
carcinomas). The number ofmitoses counted was the average
per one high power field (HPF) from ten fields (Leitz
Orthoplan, 40 x Plan objective), and graded as rare mitoses/
HPF, or >2/HPF. Tumour necrosis was graded as none,
spotty, moderate or severe (intraductal comedo necrosis was
not included).
The size of the S phase fraction (SPF) was determined
from DNA histograms produced by flow cytometry as de-
scribed in detail elsewhere (Toikkanen et al., 1989). The
rectangular method was used in their calculation. SPF was
available in 223 and 271 cases in the 1945-65 and 1980-84
series, respectively.
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Statistical methods
Frequency tables were analysed with the chi-squared test.
Comparison of age distributions was done with Mann-
Whitney's U-test. Survival was analysed with the BMDP
computer program (BMDP Statistical Software, Department
of Biomathematics, University of California, Los Angeles,
CA). Cumulative survival was estimated with the product-
limit method, and comparison of cumulative survival
between groups was performed with the log-rank test. Sur-
vival corrected for intercurrent deaths was used in statistical
calculations. When calculating survival by the month ofdiag-
nosis, diagnosis was considered to be made when the path-
ologist reported breast cancer. The relative importance of
risk factors was assessed with Cox's proportional hazard
model (Cox, 1972). All P-values are two-tailed.
The month when the first symptoms or signs caused by
breast cancer were first noticed was retrieved from the hos-
pital records (available in 681 cases), but the date of the
pathologist's report was preferred in statistical calculations,
because it was always available and exactly known.
Results
Survival corrected for intercurrent deaths by the month of
diagnosis, shown in Table I, improved considerably from
1945-65 to 1980-84. In 1945 to 1965 survival was poorer if
the diagnosis was made in January, February or August to
October than during the rest of the year (this combination of
months produced the smallest P-value in the log-rank test,
P = 0.03, n = 401). Mortality in breast cancer was greater
during these months among postmenopausal women
(P = 0.02, n = 266), but not among the premenopausal ones
(P = 0.90, n = 135, Figure 1). The difference in survival
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Figure 1 Survival corrected for intercurrent deaths by the month
of diagnosis among 401 patients with breast cancer diagnosed in
1945-65. a, Premenopausal women, -Jan-Feb/Aug-Sept-Oct
(n = 45); The rest of the months (n = 90). P = 0.90. b, post-
menopausal women, Jan-Feb/Aug-Sept-Oct (n = 108);
The rest of the months (n = 158). P = 0.02.
tended to be significant also among women without axillary
nodal metastases (pN0, P = 0.06, P = 131), but not among
the node positive ones (pN +, P = 0.45, N = 185). Except
for January, the number of women diagnosed to have breast
cancer was lower than the median during the months
associated with poorer survival (median = 33, Table I).
Mortality in breast cancer was greater if the diagnosis was
made in July to September than during the rest of the year in
1980-84 (P = 0.009, n = 337). Survival was significantly
inferior among both premenopausal and postmenopausal
women (P = 0.05, n = 65 and 0.04, n = 272, respectively,
Figure 2), but not among women with axillary nodal meta-
stases (pN +, P = 0.26, n = 134) or among those without
(pN0, P = 0.29, 162). The number of cases diagnosed during
these 3 months was less than the median (median = 29, Table
I). Survival was particularly good if the diagnosis was made
in November (P = 0.02 as compared with the the rest of the
year).
Cancers diagnosed during the months associated with less
favourable outcome had more extensive tumour necrosis
(P = 0.03 in 1945-65, and 0.02 in 1980-84, Table II), higher
mitotic count (P = 0.03 in 1945-65), and larger primary
tumour size (P = 0.02 in 1945-65) than cancers diagnosed at
other times of the year. There was no significant difference in
patient age at diagnosis, histological type or grade of cancer,
size of S phase fraction, presence of axillary nodal or distant
metastases at the time of the diagnosis, or tumour ER or PR
content.
In order to find out the relative importance of the month
of diagnosis as a prognostic factor in breast cancer, it was
entered together with postsurgical axillary nodal status
(pN + vs pNO), primary tumour size (pT3 or pT4 vs pT2 vs
pTl) and histological grade (Gr. 3 vs Gr. 2 vs Gr. 1)) into
Cox's multivariate analyses. Axillary nodal status, primary
tumour size and histological grade had all independent prog-
nostic value (P <0.001) in both series, but the month of
diagnosis (January, February, or August to October in the
1945-65 series or July to September in the 1980-84 series)
did not have independent prognostic value.
Discussion
Mortality caused by breast cancer was the greatest if cancer
was diagnosed in January or February, or in August to
October in 1945-65, or in January to September in 1980-84.
The date of the diagnosis was taken as the date of the
pathologist's report, and because the time lag between
tumour detection and the pathologist's report was longer in
1945-65 (median, 3 months, mean, 9.9 months) than in
1980-84 (median, 1 month, mean, 4.4 months), no real shift
in the time period associated with poorer outcome may have
taken place. Prognosis of cancers diagnosed in December
tended to be poor in 1980-84 (Table I), but if the cancers
Table I Survival corrected for intercurrent deaths by the month of
the diagnosis in two series of breast cancer
Diagnosis in Diagnosis in
1945 to 1965 1980 to 1984
S-year 10-year 20-year S-year
Month n survival survival survival n survival
January 34 49% 23% 19% 21 78%
February 32 51% 36% 32% 27 76%
March 43 55% 46% 35% 20 72%
April 34 58% 43% 37% 34 78%
May 35 50% 40% 40% 31 79%
June 39 57% 48% 40% 33 76%
July 30 57% 49% 39% 23 68%
August 30 53% 46% 29% 19 57%
September 28 34% 29% 29% 27 72%
October 29 52% 34% 31% 38 80%
November 37 65% 50% 38% 31 93%
December 30 52% 36% 36% 33 68%
Total 401 Total 337
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Figure 2 Survival corrected for intercurrent deaths by the month
of diagnosis among 337 patients with breast cancer diagnosed in
1980-84. a, Premenopausal women, -Jul-Aug-Sept (n = 15)
The rest of the months (n = 50). P = 0.05. b, post-
menopausal women, -Jul-Aug-Sept (n = 54); The rest
of the months (n = 218). P = 0.04.
diagnosed in December were lumped together with those
diagnosed in July to September, the P-value of survival
analysis increased marginally (from 0.0091 to 0.0094).
The difference in the final outcome by the month of the
diagnosis could be explained by seasonal hormonal influence
on breast cancer, or by changes in social behaviour, such as
deferral of medical treatment for holiday for patient or doc-
tor convenience. Seasonal variations have been described in
the incidence of a number of noninfectious human disorders,
and in the occurrence of breast cancer (Cohen et al., 1983).
Melatonin, the major hormone of the pineal gland, has been
shown to inhibit the growth of mammary tumours in animal
models of human breast cancer, and also the estrogen-
responsive human breast cancer cell line MCF-7 in culture in
physiological concentrations (Hill & Blask, 1988). On the
other hand, melatonin has been reported to increase estrogen
receptor binding activity in MCF-7 cells (Danforth et al.,
1983). Mason et al. (1990) found that women in Auckland,
New Zealand, who detected their breast cancer in October to
January (spring/summer) between 1976 and 1985 had more
favourable prognosis than those who found it during the rest
of the year, and the improved survival was found in women
aged >50 years with ER and PR positive tumours, and also
in women aged <50 years with receptor-negative tumours.
Although the natural history of most breast carcinomas is
probably long, a change in the hormonal environment could
lead to acceleration of tumour growth and an increase in the
rate of tumour detection at this time.
However, the evidence in favour of the hormonal hypo-
thesis is not conclusive. The poor prognosis of cancer
detected in August to October, and on the other hand in
January to February in the 1945-65 series is difficult to
explain with hormonal influence. A rapid change in the
biological behaviour of breast cancer between November
(good prognosis) and December/January (poor prognosis,
Table I) is poorly compatible with hormonal influence. If
prognosis associated with the months with increasing sunlight
(January to June) is compared with the months with decreas-
Table II Distribution of prognostic factors by the month of the diagnosis among 738 women
with unilateral invasive breast cancer
Diagnosis in 1945 to 1965 Diagnosis in 1980 to 1984
January, the rest July, the rest
February, of the August, of the
August, year September year
September
October
Factor n (%) n (%) P n (%) n (%) P
Tumour necrosis
none 90 (59) 147 (59) 44 (64) 204 (76)
spotty 24 (16) 51 (21) 11 (16) 41 (15)
moderate 18 (12) 36 (15) 14 (20) 23 (9)a
extensive 21 (14) 14 (6) 0.03 0.02
Mitotic count
rare 46 (30) 101 (41) 29 (42) 137 (51)
>2 107 (70) 147 (59) 0.03 40 (58) 131 (49) 0.18
Tumour size
pTI ( < 2 cm) 10 (7) 37 (15) 24 (35) 112 (42)
pT2 (2-Scm) 88 (58) 139 (56) 37 (54) 112 (42)
pT3 (>5cm) 25 (16) 45 (18) 8 (12) 43 (16)b 0.21
pT4 29 (19) 27 (11) 0.02
Age at diagnosis 0.67 0.86
Histological type 0.79 0.97
Histological grade 0.21 0.37
S phase fractionc 0.41 0.35
Axillary nodal statusd 0.23 0.39
Distant metastases at diagnosis (M1) 0.95 0.42
Estrogen receptor contente - 0.46
Progesterone receptor contentf 0.09
aModerate and extensive combined. bpT3 and pT4 combined. cThe number ofcases above and
below the median value were compared. dPost-surgical (pN) data used. n = 316 in 1945-65, and
n = 296 in 1980-84. eNo cut-off value produced P <0.2. Cut-off value 10 fmol mg-' protein
shown, n = 263. 'The cut-off value producing the smallest P-value shown (25 fmol mg-' protein,
n = 238, 52% of PR values low in July to September vs 38% during the rest of the year).
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ing light in either of the two series, no difference is found
(P =0.51 in the 1980-84 series, and 0.95 in the 1945-65
series). Furthermore, there was no difference in mortality
from breast cancer in either series if any 6-month period was
compared with the rest of the year.
The number of diagnosed cases was usually less than the
median during the months associated with unfavourable
prognosis. If the months with less than the median of diag-
nosed cases are tested against the months with cases more
than the median, the months with more diagnoses are
associated with better survival in the 1980-84 series
(P = 0.05), but not in the 1945-65 series (P = 0.26). The
smaller number of cancers detected during the months
associated with greater mortality, and the finding of more
cancers with adverse prognostic factors, with a large primary
tumour size, a high mitotic count, and extensive tumour
necrosis (Table II), might suggest that women with less ag-
gressive cancers may postpone their contact with the medical
personnel longer, and do not seek for treatment during the
summer holidays or at the Christmas time, which are popular
holiday periods. However, we find no significant difference in
the duration of symptoms or signs caused by breast cancer
preceding the diagnosis between the unfavourable months
and the rest of the year in either series, nor between June to
September and October to December in the 1980-84 series.
In the Auckland series (Mason et al., 1990) the months
associated with longer survival were October to January,
which corresponds to April to July in the Northern Hemi-
sphere. Unlike in the present series the month of initial
tumour detection was primarily recorded in the New Zealand
series, and their median delay to histological diagnosis was
about 2 months, and the mean delay about 3 months (Neave
et al., 1990, Holdaway et al., 1990). If the time lag between
tumour detection and diagnosis is assumed to be from 2 to 3
months, according to Auckland data cancers diagnosed histo-
logically in June to September or in July to October in the
Northern Hemisphere should be associated with favourable
prognosis. In the Turku data the opposite is found, cancers
diagnosed in June to September or in July to October have
inferior prognosis (P = 0.02 and 0.06, respectively, in the
1980-84 series). In the New Zealand data the lowest mean
monthly breast tumour progesterone receptor concentrations
were found in samples taken in August and September (late
winter, Holdaway et al., 1990). These apparently contradic-
tory results may not, however, refute the hormonal hypo-
thesis, because racial factors may be of importance, and the
seasonal changes in lightness are considerably greater in
Turku (latitude 60°) than in Auckland (latitude 37°).
Some breast cancers are found incidentally by the medical
personnel or in screening, and in their detection seasonal
hormonal factors are likely to have less importance. The
frequency of such cancers is known only for our 1980-84
series, where 38 breast carcinomas were found when the
breasts were investigated by a nurse in conjunction with
screening for uterine cervical cancer, and further 49 cancers
were incidentally found by medical personnel. If the screen-
detected or both screen-detected and the incidentally found
cancers are removed from the survival analysis, cancers diag-
nosed in July to September still have inferior prognosis
(P = 0.008 and 0.047, respectively), and less cancers than the
median are still diagnosed in July, August and September.
In accordance with the present data, Jacobson and
Janerich (1977) found using the New York State Cancer
Registry tumour ER content to be ten times higher in May
than in September, May to have the highest frequency of
tumour diagnosis, and August, September and December to
have the lowest. On the other hand, Hrushesky et al. (1979)
from Minneapolis found ER content to be higher in late
autumn than in spring, the month with the highest concen-
trations was November.
In summary, prognosis of breast cancer was dependent on
the month of diagnosis, cancers diagnosed in July to
September had poorer prognosis. In a multivariate analysis
the season of breast cancer diagnosis was not an independent
prognostic factor. The reasons for the altering prognosis by
the month of the diagnosis remain speculative, but more
cancers with less adverse prognostic features were detected at
other times of the year.
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